CTI Announces That The EORTC Completes Enrollment In Phase II Clinical Trial Of Brostallicin
Cell Therapeutics, Inc.'s (CTI) (NASDAQ and MTA: CTIC) subsidiary Systems Medicine (SM) has announced that planned enrollment is complete in the European Organization for Research and Treatment of Cancer (EORTC) randomized phase II clinical trial of brostallicin in patients with newly diagnosed advanced or metastatic soft tissue sarcoma who have had no prior chemotherapy. The primary endpoint of the trial is progression-free survival at six months.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment